TY - JOUR
T1 - Development of a Thalassemia International Prognostic Scoring System (TIPSS)
AU - International Working Group on Thalassemia (IWG-THAL)
AU - Vitrano, Angela
AU - Musallam, Khaled M.
AU - Meloni, Antonella
AU - Karimi, Mehran
AU - Daar, Shahina
AU - Ricchi, Paolo
AU - Costantini, Silvia
AU - Vlachaki, Efthymia
AU - Di Marco, Vito
AU - El-Beshlawy, Amal
AU - Hajipour, Mahmoud
AU - Ansari, Saqib Hussain
AU - Filosa, Aldo
AU - Ceci, Adriana
AU - Singer, Sylvia Titi
AU - Naserullah, Zaki A.
AU - Pepe, Alessia
AU - Cademartiri, Filippo
AU - Pollina, Sebastiano Addario
AU - Scondotto, Salvatore
AU - Dardanoni, Gabriella
AU - Bonifazi, Fedele
AU - Sankaran, Vijay G.
AU - Vichinsky, Elliott
AU - Taher, Ali T.
AU - Maggio, Aurelio
N1 - Funding Information:
The authors would like to thank all patients for agreeing to participate in this study. The support by Foundation Franco and Piera Cutino is appreciated. Data were collected and stored on the IHR electronic platform ( www.sanitasicilia.eu/IWG) and can be available upon request from the corresponding author. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Publisher Copyright:
© 2022
PY - 2023/3
Y1 - 2023/3
N2 - A prognostic scoring system that can differentiate β-thalassemia patients based on mortality risk is lacking. We analysed data from 3145 β-thalassemia patients followed through a retrospective cohort design for the outcome of death. An a priori list of prognostic variables was collected. β Coefficients from a multivariate cox regression model were used from a development dataset (n = 2516) to construct a formula for a Thalassemia International Prognostic Scoring System (TIPSS) which was subsequently applied to a validation dataset (n = 629). The median duration of observation was 10.0 years. The TIPSS score formula was constructed as exp (1.4 × heart disease + 0.9 × liver disease + 0.9 × diabetes + 0.9 × sepsis + 0.6 × alanine aminotransferase ≥42 IU/L + 0.6 × hemoglobin ≤9 g/dL + 0.4 × serum ferritin ≥1850 ng/mL). TIPSS score thresholds of greatest differentiation were assigned as <2.0 (low-risk), 2.0 to <5.0 (intermediate-risk), and ≥5.0 (high-risk). The TIPSS score was a good predictor for the outcome of death in the validation dataset (AUC: 0.722, 95%CI: 0.641–0.804) and survival was significantly different between patients in the three risk categories (P < 0.001). Compared to low-risk patients, the hazard ratio for death was 2.778 (95%CI: 1.335–5.780) in patients with intermediate-risk and 6.431 (95%CI: 3.151–13.128) in patients with high-risk. This study provides a novel tool to support mortality risk categorization for patients with β-thalassemia that could help management and research decisions.
AB - A prognostic scoring system that can differentiate β-thalassemia patients based on mortality risk is lacking. We analysed data from 3145 β-thalassemia patients followed through a retrospective cohort design for the outcome of death. An a priori list of prognostic variables was collected. β Coefficients from a multivariate cox regression model were used from a development dataset (n = 2516) to construct a formula for a Thalassemia International Prognostic Scoring System (TIPSS) which was subsequently applied to a validation dataset (n = 629). The median duration of observation was 10.0 years. The TIPSS score formula was constructed as exp (1.4 × heart disease + 0.9 × liver disease + 0.9 × diabetes + 0.9 × sepsis + 0.6 × alanine aminotransferase ≥42 IU/L + 0.6 × hemoglobin ≤9 g/dL + 0.4 × serum ferritin ≥1850 ng/mL). TIPSS score thresholds of greatest differentiation were assigned as <2.0 (low-risk), 2.0 to <5.0 (intermediate-risk), and ≥5.0 (high-risk). The TIPSS score was a good predictor for the outcome of death in the validation dataset (AUC: 0.722, 95%CI: 0.641–0.804) and survival was significantly different between patients in the three risk categories (P < 0.001). Compared to low-risk patients, the hazard ratio for death was 2.778 (95%CI: 1.335–5.780) in patients with intermediate-risk and 6.431 (95%CI: 3.151–13.128) in patients with high-risk. This study provides a novel tool to support mortality risk categorization for patients with β-thalassemia that could help management and research decisions.
KW - Management
KW - Mortality
KW - Outcomes
KW - Prognosis
KW - Survival
KW - Thalassemia
UR - http://www.scopus.com/inward/record.url?scp=85143487929&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143487929&partnerID=8YFLogxK
U2 - 10.1016/j.bcmd.2022.102710
DO - 10.1016/j.bcmd.2022.102710
M3 - Review article
C2 - 36463683
AN - SCOPUS:85143487929
SN - 1079-9796
VL - 99
JO - Blood Cells, Molecules, and Diseases
JF - Blood Cells, Molecules, and Diseases
M1 - 102710
ER -